Integra LifeSciences (NASDAQ:IART) Issues Quarterly Earnings Results

Integra LifeSciences (NASDAQ:IART) announced its quarterly earnings data on Wednesday. The life sciences company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.56 by $0.03, FiscalAI reports. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $411.18 million during the quarter, compared to the consensus estimate of $413.16 million. During the same period in the previous year, the business earned ($0.07) earnings per share.

Integra LifeSciences Price Performance

Shares of IART opened at $13.33 on Wednesday. The business has a 50-day simple moving average of $15.67 and a two-hundred day simple moving average of $15.55. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The stock has a market cap of $1.04 billion, a PE ratio of -148.09, a PEG ratio of 0.71 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wells Fargo & Company set a $15.00 price target on Integra LifeSciences in a research note on Saturday, October 3rd. BMO Capital Markets reduced their price objective on Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating on the stock in a research note on Monday, October 5th. Citigroup reiterated a “neutral” rating and issued a $15.00 target price (down from $19.00) on shares of Integra LifeSciences in a research report on Monday, October 5th. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Weiss Ratings downgraded Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $16.71.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported adjusted EPS of $0.59, ahead of the $0.56 consensus estimate and up from $0.54 a year earlier. GAAP EPS improved to $0.19 from a $0.07 loss, while operating cash flow rose to $96 million. Integra LifeSciences Surpasses Q3 Earnings Estimates
• Positive Sentiment: The company completed a $2.1 billion debt refinancing, extending maturities and increasing near-term covenant flexibility. Net debt declined to approximately $1.5 billion, and the leverage ratio improved to 3.8x, reducing near-term refinancing risk. Integra Announces Completion of Refinancing Transactions
• Neutral Sentiment: Third-quarter revenue increased 2.3% year over year to $411.2 million, slightly below the $413.2 million analyst consensus. Specialty Surgery revenue grew 3.9%, led by neurosurgery, but Instruments and ENT declined modestly. Integra Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Flood damage at the Cincinnati facility reduced quarterly revenue by about $7 million, while Tissue Reconstruction revenue fell 2.2%. Integra expects fourth-quarter revenue of $413 million to $433 million, implying a year-over-year decline of up to 5.2%, although full-year guidance was reaffirmed. Integra Swings to Earnings in Q3 and Guides Q4 and FY26
• Negative Sentiment: Profitability remains pressured by a lower adjusted gross margin of 61.1% versus 62.9% last year, and refinancing is expected to increase interest expense. Truist also cut its price target from $19 to $15, reinforcing concerns about slower growth and execution risks. Truist Cuts Integra LifeSciences Price Target

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.